臨床外科71巻5号

2016年05月発行

特集 外科臨床研究のノウハウと重要研究の総まとめ Part2：押さえておきたい外科臨床研究の総まとめ

大腸癌

著者： 永田洋士¹ 石原聡一郎¹ 渡邉聡明¹

所属機関： ¹東京大学腫瘍外科

ページ範囲：P.558 - P.563

【ポイント】
◆本邦では独自の取扱い規約や治療ガイドラインを作成し，良好な治療成績を収めてきた．
◆大腸癌の治療成績は欧米と日本で異なるため，本邦からのエビデンスが求められる．
◆多くの臨床試験が進行中であり，結果が注目される．

参考文献

1）Gerota D：Die lymphgefässe des rectums und des anus. Arch Anat Physiol 181：240-256, 1895

2）仙波嘉清：直腸淋巴管系統に関する解剖学的研究．福岡医大誌20：1213-1268，1927

3）久留　勝：直腸癌．日外会誌41：832-877，1940

4）高橋　孝，梶谷　鐶：直腸癌における側方向リンパ流への転移とその廓清の意義について．日本大腸肛門病会誌31：207-219，1978

5）Sauer I, Bacon HE：Influence of lateral spread of cancer of the rectum on radicability of operation and prognosis. Am J Surg 81：111-120, 1951

6）Bacon HE, Dirbas F, Myers TB, et al：Extensive lymphad enectomy and high ligation of the inferior mesenteric artery for carcinoma of the left colon and rectum. Dis Colon Rectum 1：457-464, 1958

7）Stearns MW Jr, Deddish MR：Five-year results of abdominopelvic lymph node dissection for carcinoma of the rectum. Dis Colon Rectum 2：169-172, 1959

8）小松原正吉：直腸癌根治手術における膀胱ならびに性機能障害の防止に関する臨床的研究．岡山医会誌90：101-119，1978

9）土屋周二，池　秀之，大木　繁：大腸癌の手術．自律神経を温存する直腸癌手術．手術37：1367-1373，1983

10）Sugihara K, Kobayashi H, Kato T, et al：Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49：1663-1672, 2006

11）大腸癌研究会：大腸癌治療ガイドライン 医師用，2014年版．金原出版，2014

12）Monson JR, Weiser MR, Buie WD, et al：Practice parameters for the management of rectal cancer（revised）. Dis Colon Rectum 56：535-550, 2013

13）Watanabe T, Tsurita G, Muto T, et al：Extended lymphadenectomy and preoperative radiotherapy for lower rectal cancers. Surgery 132：27-33, 2002

14）Nagawa H, Muto T, Sunouchi K, et al：Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy. Dis Colon Rectum 44：1274-1280, 2001

15）Fujita S, Akasu T, Mizusawa J, et al：Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer（JCOG0212）：results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol 13：616-621, 2012

16）Douillard JY, Hoff PM, Skillings JR, et al：Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20：3605-3616, 2002

17）Shirao K, Hoff PM, Ohtsu A, et al：Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur（UFT）plus oral leucovorin（LV）regimen between Japanese and American patients with advanced colorectal cancer：joint United States and Japan study of UFT/LV. J Clin Oncol 22：3466-3474, 2004

18）Lembersky BC, Wieand HS, Petrelli NJ, et al：Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage Ⅱ and Ⅲ carcinoma of the colon：results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24：2059-2064, 2006

19）Shimada Y, Hamaguchi T, Mizusawa J, et al：Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection：final results of JCOG0205. Eur J Cancer 50：2231-2240, 2014

20）Ishiguro M, Mochizuki H, Tomita N, et al：Study protocol of the SACURA trial：a randomized phase Ⅲ trial of efficacy and safety of UFT as adjuvant chemotherapy for stage Ⅱ colon cancer. BMC Cancer 12：281, 2012

21）Yoshida M, Ishiguro M, Ikejiri K, et al：S-1 as adjuvant chemotherapy for stage Ⅲ colon cancer：a randomized phase Ⅲ study（ACTS-CC trial）. Ann Oncol 25：1743-1749, 2014

22）Shirao K, Ohtsu A, Takada H, et al：Phase Ⅱ study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100：2355-2361, 2004

23）Van den Brande J, Schoffski P, Schellens JH, et al：EORTC Early Clinical Studies Group early phase Ⅱ trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88：648-653, 2003

24）Yamada Y, Takahari D, Matsumoto H, et al：Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer（SOFT）：an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14：1278-1286, 2013

25）Muro K, Boku N, Shimada Y, et al：Irinotecan plus S-1（IRIS）versus fluorouracil and folinic acid plus irinotecan（FOLFIRI）as second-line chemotherapy for metastatic colorectal cancer：a randomised phase 2/3 non-inferiority study（FIRIS study）. Lancet Oncol 11：853-860, 2010

26）Goto A, Yamada Y, Yasui H, et al：Phase Ⅱ study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17：968-973, 2006

27）Yamada Y, Yamaguchi T, Matsumoto H, et al：Phase Ⅱ study of oral S-1 with irinotecan and bevacizumab（SIRB）as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 30：1690-1696, 2012

28）Komatsu Y, Ishioka C, Shimada K, et al：Study protocol of the TRICOLORE trial：a randomized phase Ⅲ study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. BMC Cancer 15：626, 2015

29）Hoff PM, Ansari R, Batist G, et al：Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer：results of a randomized phase Ⅲ study. J Clin Oncol 19：2282-2292, 2001

30）Van Cutsem E, Twelves C, Cassidy J, et al：Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer：results of a large phase Ⅲ study. J Clin Oncol 19：4097-4106, 2001

31）Saltz LB, Clarke S, Diaz-Rubio E, et al：Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer：a randomized phase Ⅲ study. J Clin Oncol 26：2013-2019, 2008

32）Twelves C, Wong A, Nowacki MP, et al：Capecitabine as adjuvant treatment for stage Ⅲ colon cancer. N Engl J Med 352：2696-2704, 2005

33）末永光邦：【最新臨床大腸癌学—基礎研究から臨床応用へ】大腸癌の治療．化学療法．切除不能進行・再発大腸癌の治療戦略におけるTAS102の位置づけ．日臨73：510-514，2015

34）Yoshino T, Mizunuma N, Yamazaki K, et al：TAS-102 monotherapy for pretreated metastatic colorectal cancer：a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13：993-1001, 2012

35）Mayer RJ, Van Cutsem E, Falcone A, et al：Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372：1909-1919, 2015